nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—SLC16A1—Methotrexate—testicular cancer	0.151	0.168	CbGbCtD
Nateglinide—PTGS1—Ifosfamide—testicular cancer	0.114	0.127	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.091	0.101	CbGbCtD
Nateglinide—CYP3A7—Ifosfamide—testicular cancer	0.091	0.101	CbGbCtD
Nateglinide—ABCC4—Methotrexate—testicular cancer	0.0724	0.0805	CbGbCtD
Nateglinide—CYP3A5—Ifosfamide—testicular cancer	0.0683	0.076	CbGbCtD
Nateglinide—PTGS1—Etoposide—testicular cancer	0.0544	0.0605	CbGbCtD
Nateglinide—CYP2C9—Ifosfamide—testicular cancer	0.0458	0.051	CbGbCtD
Nateglinide—CYP3A5—Etoposide—testicular cancer	0.0326	0.0363	CbGbCtD
Nateglinide—SLC22A6—Methotrexate—testicular cancer	0.0315	0.0351	CbGbCtD
Nateglinide—ALB—Methotrexate—testicular cancer	0.0268	0.0299	CbGbCtD
Nateglinide—CYP3A4—Ifosfamide—testicular cancer	0.0266	0.0296	CbGbCtD
Nateglinide—CYP2C9—Cisplatin—testicular cancer	0.0223	0.0248	CbGbCtD
Nateglinide—CYP2D6—Vinblastine—testicular cancer	0.0222	0.0247	CbGbCtD
Nateglinide—CYP3A4—Vinblastine—testicular cancer	0.0141	0.0157	CbGbCtD
Nateglinide—CYP2D6—Doxorubicin—testicular cancer	0.0136	0.0152	CbGbCtD
Nateglinide—CYP3A4—Etoposide—testicular cancer	0.0127	0.0142	CbGbCtD
Nateglinide—CYP3A4—Doxorubicin—testicular cancer	0.00868	0.00966	CbGbCtD
Nateglinide—PPARG—Teniposide—Etoposide—testicular cancer	0.00448	1	CbGdCrCtD
Nateglinide—Trauma—Bleomycin—testicular cancer	0.00386	0.0412	CcSEcCtD
Nateglinide—Injury—Bleomycin—testicular cancer	0.00145	0.0155	CcSEcCtD
Nateglinide—Urine output increased—Ifosfamide—testicular cancer	0.00142	0.0151	CcSEcCtD
Nateglinide—Neuropathy peripheral—Chlorambucil—testicular cancer	0.0013	0.0139	CcSEcCtD
Nateglinide—Polyuria—Ifosfamide—testicular cancer	0.0013	0.0138	CcSEcCtD
Nateglinide—Jaundice—Chlorambucil—testicular cancer	0.00129	0.0138	CcSEcCtD
Nateglinide—Neuropathy peripheral—Vinblastine—testicular cancer	0.00119	0.0127	CcSEcCtD
Nateglinide—Osteoarthritis—Ifosfamide—testicular cancer	0.00114	0.0122	CcSEcCtD
Nateglinide—Erythema multiforme—Chlorambucil—testicular cancer	0.00113	0.012	CcSEcCtD
Nateglinide—Polyuria—Cisplatin—testicular cancer	0.00112	0.0119	CcSEcCtD
Nateglinide—Tremor—Chlorambucil—testicular cancer	0.000971	0.0104	CcSEcCtD
Nateglinide—Neuropathy peripheral—Ifosfamide—testicular cancer	0.00086	0.00918	CcSEcCtD
Nateglinide—Hepatobiliary disease—Ifosfamide—testicular cancer	0.00083	0.00886	CcSEcCtD
Nateglinide—Sweating increased—Cisplatin—testicular cancer	0.000827	0.00882	CcSEcCtD
Nateglinide—Erythema multiforme—Dactinomycin—testicular cancer	0.000813	0.00868	CcSEcCtD
Nateglinide—Hepatic enzyme increased—Methotrexate—testicular cancer	0.000785	0.00838	CcSEcCtD
Nateglinide—Arthropathy—Epirubicin—testicular cancer	0.000764	0.00815	CcSEcCtD
Nateglinide—Sweating increased—Etoposide—testicular cancer	0.000757	0.00808	CcSEcCtD
Nateglinide—Erythema multiforme—Ifosfamide—testicular cancer	0.000745	0.00795	CcSEcCtD
Nateglinide—Dyspepsia—Chlorambucil—testicular cancer	0.000745	0.00795	CcSEcCtD
Nateglinide—Neuropathy peripheral—Cisplatin—testicular cancer	0.000742	0.00792	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000731	0.0078	CcSEcCtD
Nateglinide—Fatigue—Chlorambucil—testicular cancer	0.00073	0.00779	CcSEcCtD
Nateglinide—Hepatobiliary disease—Cisplatin—testicular cancer	0.000716	0.00764	CcSEcCtD
Nateglinide—Immune system disorder—Ifosfamide—testicular cancer	0.000712	0.0076	CcSEcCtD
Nateglinide—Arthropathy—Doxorubicin—testicular cancer	0.000707	0.00755	CcSEcCtD
Nateglinide—Cough—Bleomycin—testicular cancer	0.0007	0.00748	CcSEcCtD
Nateglinide—Gastrointestinal pain—Chlorambucil—testicular cancer	0.000692	0.00739	CcSEcCtD
Nateglinide—Malnutrition—Ifosfamide—testicular cancer	0.000686	0.00732	CcSEcCtD
Nateglinide—Neuropathy peripheral—Etoposide—testicular cancer	0.000679	0.00725	CcSEcCtD
Nateglinide—Jaundice—Etoposide—testicular cancer	0.000676	0.00721	CcSEcCtD
Nateglinide—Urticaria—Chlorambucil—testicular cancer	0.000672	0.00718	CcSEcCtD
Nateglinide—Urine output increased—Methotrexate—testicular cancer	0.000671	0.00716	CcSEcCtD
Nateglinide—Abdominal pain—Chlorambucil—testicular cancer	0.000669	0.00714	CcSEcCtD
Nateglinide—Hepatobiliary disease—Etoposide—testicular cancer	0.000656	0.007	CcSEcCtD
Nateglinide—Gastrointestinal pain—Vinblastine—testicular cancer	0.000634	0.00677	CcSEcCtD
Nateglinide—Hypersensitivity—Chlorambucil—testicular cancer	0.000624	0.00666	CcSEcCtD
Nateglinide—Polyuria—Methotrexate—testicular cancer	0.000614	0.00655	CcSEcCtD
Nateglinide—Immune system disorder—Cisplatin—testicular cancer	0.000614	0.00655	CcSEcCtD
Nateglinide—Abdominal pain—Vinblastine—testicular cancer	0.000613	0.00654	CcSEcCtD
Nateglinide—Asthenia—Chlorambucil—testicular cancer	0.000607	0.00648	CcSEcCtD
Nateglinide—Palpitations—Ifosfamide—testicular cancer	0.000606	0.00647	CcSEcCtD
Nateglinide—Pruritus—Chlorambucil—testicular cancer	0.000599	0.00639	CcSEcCtD
Nateglinide—Cough—Ifosfamide—testicular cancer	0.000599	0.00639	CcSEcCtD
Nateglinide—Malnutrition—Cisplatin—testicular cancer	0.000591	0.00631	CcSEcCtD
Nateglinide—Erythema multiforme—Etoposide—testicular cancer	0.000588	0.00628	CcSEcCtD
Nateglinide—Diarrhoea—Chlorambucil—testicular cancer	0.000579	0.00618	CcSEcCtD
Nateglinide—Hypersensitivity—Vinblastine—testicular cancer	0.000571	0.0061	CcSEcCtD
Nateglinide—Immune system disorder—Etoposide—testicular cancer	0.000562	0.006	CcSEcCtD
Nateglinide—Asthenia—Vinblastine—testicular cancer	0.000556	0.00594	CcSEcCtD
Nateglinide—Tremor—Cisplatin—testicular cancer	0.000554	0.00591	CcSEcCtD
Nateglinide—Hyperhidrosis—Ifosfamide—testicular cancer	0.000541	0.00578	CcSEcCtD
Nateglinide—Osteoarthritis—Methotrexate—testicular cancer	0.000539	0.00575	CcSEcCtD
Nateglinide—Vomiting—Chlorambucil—testicular cancer	0.000538	0.00574	CcSEcCtD
Nateglinide—Increased appetite—Epirubicin—testicular cancer	0.000537	0.00573	CcSEcCtD
Nateglinide—Diarrhoea—Vinblastine—testicular cancer	0.000531	0.00566	CcSEcCtD
Nateglinide—Fatigue—Dactinomycin—testicular cancer	0.000527	0.00562	CcSEcCtD
Nateglinide—Back pain—Etoposide—testicular cancer	0.000524	0.00559	CcSEcCtD
Nateglinide—Urticaria—Bleomycin—testicular cancer	0.00052	0.00555	CcSEcCtD
Nateglinide—Hypoglycaemia—Epirubicin—testicular cancer	0.000517	0.00552	CcSEcCtD
Nateglinide—Dizziness—Vinblastine—testicular cancer	0.000513	0.00547	CcSEcCtD
Nateglinide—Osteoarthritis—Epirubicin—testicular cancer	0.000504	0.00538	CcSEcCtD
Nateglinide—Nausea—Chlorambucil—testicular cancer	0.000503	0.00537	CcSEcCtD
Nateglinide—Gastrointestinal pain—Dactinomycin—testicular cancer	0.0005	0.00533	CcSEcCtD
Nateglinide—Increased appetite—Doxorubicin—testicular cancer	0.000497	0.0053	CcSEcCtD
Nateglinide—Vomiting—Vinblastine—testicular cancer	0.000493	0.00526	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000483	0.00516	CcSEcCtD
Nateglinide—Abdominal pain—Dactinomycin—testicular cancer	0.000483	0.00516	CcSEcCtD
Nateglinide—Fatigue—Ifosfamide—testicular cancer	0.000483	0.00515	CcSEcCtD
Nateglinide—Hypersensitivity—Bleomycin—testicular cancer	0.000483	0.00515	CcSEcCtD
Nateglinide—Hypoglycaemia—Doxorubicin—testicular cancer	0.000478	0.0051	CcSEcCtD
Nateglinide—Cough—Etoposide—testicular cancer	0.000473	0.00505	CcSEcCtD
Nateglinide—Asthenia—Bleomycin—testicular cancer	0.00047	0.00502	CcSEcCtD
Nateglinide—Osteoarthritis—Doxorubicin—testicular cancer	0.000467	0.00498	CcSEcCtD
Nateglinide—Hyperhidrosis—Cisplatin—testicular cancer	0.000467	0.00498	CcSEcCtD
Nateglinide—Pruritus—Bleomycin—testicular cancer	0.000463	0.00495	CcSEcCtD
Nateglinide—Nausea—Vinblastine—testicular cancer	0.000461	0.00492	CcSEcCtD
Nateglinide—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000458	0.00489	CcSEcCtD
Nateglinide—Hypersensitivity—Dactinomycin—testicular cancer	0.00045	0.0048	CcSEcCtD
Nateglinide—Urticaria—Ifosfamide—testicular cancer	0.000445	0.00475	CcSEcCtD
Nateglinide—Abdominal pain—Ifosfamide—testicular cancer	0.000443	0.00472	CcSEcCtD
Nateglinide—Asthenia—Dactinomycin—testicular cancer	0.000438	0.00468	CcSEcCtD
Nateglinide—Influenza—Epirubicin—testicular cancer	0.000436	0.00465	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000433	0.00462	CcSEcCtD
Nateglinide—Hyperhidrosis—Etoposide—testicular cancer	0.000427	0.00456	CcSEcCtD
Nateglinide—Bronchitis—Epirubicin—testicular cancer	0.000419	0.00447	CcSEcCtD
Nateglinide—Diarrhoea—Dactinomycin—testicular cancer	0.000418	0.00446	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000417	0.00445	CcSEcCtD
Nateglinide—Vomiting—Bleomycin—testicular cancer	0.000416	0.00445	CcSEcCtD
Nateglinide—Rash—Bleomycin—testicular cancer	0.000413	0.00441	CcSEcCtD
Nateglinide—Dermatitis—Bleomycin—testicular cancer	0.000413	0.0044	CcSEcCtD
Nateglinide—Hypersensitivity—Ifosfamide—testicular cancer	0.000412	0.0044	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000405	0.00432	CcSEcCtD
Nateglinide—Influenza—Doxorubicin—testicular cancer	0.000403	0.0043	CcSEcCtD
Nateglinide—Asthenia—Ifosfamide—testicular cancer	0.000402	0.00429	CcSEcCtD
Nateglinide—Sweating—Methotrexate—testicular cancer	0.000398	0.00425	CcSEcCtD
Nateglinide—Pruritus—Ifosfamide—testicular cancer	0.000396	0.00423	CcSEcCtD
Nateglinide—Hepatobiliary disease—Methotrexate—testicular cancer	0.000393	0.00419	CcSEcCtD
Nateglinide—Nausea—Bleomycin—testicular cancer	0.000389	0.00415	CcSEcCtD
Nateglinide—Vomiting—Dactinomycin—testicular cancer	0.000388	0.00415	CcSEcCtD
Nateglinide—Bronchitis—Doxorubicin—testicular cancer	0.000388	0.00414	CcSEcCtD
Nateglinide—Rash—Dactinomycin—testicular cancer	0.000385	0.00411	CcSEcCtD
Nateglinide—Diarrhoea—Ifosfamide—testicular cancer	0.000383	0.00409	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Etoposide—testicular cancer	0.000382	0.00407	CcSEcCtD
Nateglinide—Fatigue—Etoposide—testicular cancer	0.000381	0.00407	CcSEcCtD
Nateglinide—Neuropathy peripheral—Epirubicin—testicular cancer	0.000381	0.00407	CcSEcCtD
Nateglinide—Jaundice—Epirubicin—testicular cancer	0.000379	0.00404	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000375	0.004	CcSEcCtD
Nateglinide—Sweating—Epirubicin—testicular cancer	0.000373	0.00398	CcSEcCtD
Nateglinide—Dizziness—Ifosfamide—testicular cancer	0.00037	0.00395	CcSEcCtD
Nateglinide—Hepatobiliary disease—Epirubicin—testicular cancer	0.000367	0.00392	CcSEcCtD
Nateglinide—Nausea—Dactinomycin—testicular cancer	0.000363	0.00387	CcSEcCtD
Nateglinide—Gastrointestinal pain—Etoposide—testicular cancer	0.000362	0.00386	CcSEcCtD
Nateglinide—Vomiting—Ifosfamide—testicular cancer	0.000356	0.0038	CcSEcCtD
Nateglinide—Hypersensitivity—Cisplatin—testicular cancer	0.000356	0.0038	CcSEcCtD
Nateglinide—Rash—Ifosfamide—testicular cancer	0.000353	0.00377	CcSEcCtD
Nateglinide—Dermatitis—Ifosfamide—testicular cancer	0.000353	0.00376	CcSEcCtD
Nateglinide—Erythema multiforme—Methotrexate—testicular cancer	0.000352	0.00376	CcSEcCtD
Nateglinide—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000352	0.00376	CcSEcCtD
Nateglinide—Urticaria—Etoposide—testicular cancer	0.000351	0.00375	CcSEcCtD
Nateglinide—Jaundice—Doxorubicin—testicular cancer	0.00035	0.00374	CcSEcCtD
Nateglinide—Abdominal pain—Etoposide—testicular cancer	0.000349	0.00373	CcSEcCtD
Nateglinide—Asthenia—Cisplatin—testicular cancer	0.000346	0.0037	CcSEcCtD
Nateglinide—Sweating—Doxorubicin—testicular cancer	0.000345	0.00368	CcSEcCtD
Nateglinide—Oedema peripheral—Epirubicin—testicular cancer	0.000344	0.00367	CcSEcCtD
Nateglinide—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00034	0.00363	CcSEcCtD
Nateglinide—Immune system disorder—Methotrexate—testicular cancer	0.000337	0.00359	CcSEcCtD
Nateglinide—Nausea—Ifosfamide—testicular cancer	0.000332	0.00355	CcSEcCtD
Nateglinide—Diarrhoea—Cisplatin—testicular cancer	0.00033	0.00352	CcSEcCtD
Nateglinide—Erythema multiforme—Epirubicin—testicular cancer	0.00033	0.00352	CcSEcCtD
Nateglinide—Hypersensitivity—Etoposide—testicular cancer	0.000326	0.00348	CcSEcCtD
Nateglinide—Malnutrition—Methotrexate—testicular cancer	0.000324	0.00346	CcSEcCtD
Nateglinide—Oedema peripheral—Doxorubicin—testicular cancer	0.000318	0.00339	CcSEcCtD
Nateglinide—Asthenia—Etoposide—testicular cancer	0.000317	0.00339	CcSEcCtD
Nateglinide—Immune system disorder—Epirubicin—testicular cancer	0.000315	0.00336	CcSEcCtD
Nateglinide—Back pain—Methotrexate—testicular cancer	0.000314	0.00335	CcSEcCtD
Nateglinide—Pruritus—Etoposide—testicular cancer	0.000313	0.00334	CcSEcCtD
Nateglinide—Vomiting—Cisplatin—testicular cancer	0.000307	0.00328	CcSEcCtD
Nateglinide—Erythema multiforme—Doxorubicin—testicular cancer	0.000305	0.00326	CcSEcCtD
Nateglinide—Rash—Cisplatin—testicular cancer	0.000304	0.00325	CcSEcCtD
Nateglinide—Dermatitis—Cisplatin—testicular cancer	0.000304	0.00325	CcSEcCtD
Nateglinide—Malnutrition—Epirubicin—testicular cancer	0.000304	0.00324	CcSEcCtD
Nateglinide—Diarrhoea—Etoposide—testicular cancer	0.000302	0.00323	CcSEcCtD
Nateglinide—ABCC8—seminal vesicle—testicular cancer	0.0003	0.0859	CbGeAlD
Nateglinide—Back pain—Epirubicin—testicular cancer	0.000294	0.00314	CcSEcCtD
Nateglinide—Dizziness—Etoposide—testicular cancer	0.000292	0.00312	CcSEcCtD
Nateglinide—Immune system disorder—Doxorubicin—testicular cancer	0.000292	0.00311	CcSEcCtD
Nateglinide—Nausea—Cisplatin—testicular cancer	0.000287	0.00306	CcSEcCtD
Nateglinide—Cough—Methotrexate—testicular cancer	0.000283	0.00302	CcSEcCtD
Nateglinide—Vomiting—Etoposide—testicular cancer	0.000281	0.003	CcSEcCtD
Nateglinide—Malnutrition—Doxorubicin—testicular cancer	0.000281	0.003	CcSEcCtD
Nateglinide—Rash—Etoposide—testicular cancer	0.000279	0.00298	CcSEcCtD
Nateglinide—Dermatitis—Etoposide—testicular cancer	0.000279	0.00297	CcSEcCtD
Nateglinide—Back pain—Doxorubicin—testicular cancer	0.000272	0.0029	CcSEcCtD
Nateglinide—Palpitations—Epirubicin—testicular cancer	0.000268	0.00286	CcSEcCtD
Nateglinide—Cough—Epirubicin—testicular cancer	0.000265	0.00283	CcSEcCtD
Nateglinide—Nausea—Etoposide—testicular cancer	0.000263	0.0028	CcSEcCtD
Nateglinide—Hyperhidrosis—Methotrexate—testicular cancer	0.000256	0.00273	CcSEcCtD
Nateglinide—Palpitations—Doxorubicin—testicular cancer	0.000248	0.00265	CcSEcCtD
Nateglinide—Cough—Doxorubicin—testicular cancer	0.000245	0.00262	CcSEcCtD
Nateglinide—PPARG—embryo—testicular cancer	0.000243	0.0698	CbGeAlD
Nateglinide—Hyperhidrosis—Epirubicin—testicular cancer	0.00024	0.00256	CcSEcCtD
Nateglinide—Dyspepsia—Methotrexate—testicular cancer	0.000233	0.00249	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000229	0.00244	CcSEcCtD
Nateglinide—Fatigue—Methotrexate—testicular cancer	0.000228	0.00244	CcSEcCtD
Nateglinide—Hyperhidrosis—Doxorubicin—testicular cancer	0.000222	0.00237	CcSEcCtD
Nateglinide—Dyspepsia—Epirubicin—testicular cancer	0.000218	0.00233	CcSEcCtD
Nateglinide—Gastrointestinal pain—Methotrexate—testicular cancer	0.000217	0.00231	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000214	0.00228	CcSEcCtD
Nateglinide—Fatigue—Epirubicin—testicular cancer	0.000214	0.00228	CcSEcCtD
Nateglinide—Urticaria—Methotrexate—testicular cancer	0.00021	0.00225	CcSEcCtD
Nateglinide—Abdominal pain—Methotrexate—testicular cancer	0.000209	0.00223	CcSEcCtD
Nateglinide—Gastrointestinal pain—Epirubicin—testicular cancer	0.000203	0.00216	CcSEcCtD
Nateglinide—Dyspepsia—Doxorubicin—testicular cancer	0.000202	0.00215	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000198	0.00211	CcSEcCtD
Nateglinide—Fatigue—Doxorubicin—testicular cancer	0.000198	0.00211	CcSEcCtD
Nateglinide—SLC16A1—gonad—testicular cancer	0.000197	0.0564	CbGeAlD
Nateglinide—Urticaria—Epirubicin—testicular cancer	0.000197	0.0021	CcSEcCtD
Nateglinide—Abdominal pain—Epirubicin—testicular cancer	0.000196	0.00209	CcSEcCtD
Nateglinide—Hypersensitivity—Methotrexate—testicular cancer	0.000195	0.00208	CcSEcCtD
Nateglinide—KCNJ11—female gonad—testicular cancer	0.000191	0.0547	CbGeAlD
Nateglinide—Asthenia—Methotrexate—testicular cancer	0.00019	0.00203	CcSEcCtD
Nateglinide—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000188	0.002	CcSEcCtD
Nateglinide—Pruritus—Methotrexate—testicular cancer	0.000187	0.002	CcSEcCtD
Nateglinide—Hypersensitivity—Epirubicin—testicular cancer	0.000183	0.00195	CcSEcCtD
Nateglinide—Urticaria—Doxorubicin—testicular cancer	0.000182	0.00194	CcSEcCtD
Nateglinide—Abdominal pain—Doxorubicin—testicular cancer	0.000181	0.00194	CcSEcCtD
Nateglinide—Diarrhoea—Methotrexate—testicular cancer	0.000181	0.00193	CcSEcCtD
Nateglinide—SLC15A2—seminal vesicle—testicular cancer	0.000179	0.0513	CbGeAlD
Nateglinide—Asthenia—Epirubicin—testicular cancer	0.000178	0.0019	CcSEcCtD
Nateglinide—Pruritus—Epirubicin—testicular cancer	0.000175	0.00187	CcSEcCtD
Nateglinide—Dizziness—Methotrexate—testicular cancer	0.000175	0.00187	CcSEcCtD
Nateglinide—Diarrhoea—Epirubicin—testicular cancer	0.00017	0.00181	CcSEcCtD
Nateglinide—Hypersensitivity—Doxorubicin—testicular cancer	0.000169	0.0018	CcSEcCtD
Nateglinide—Vomiting—Methotrexate—testicular cancer	0.000168	0.0018	CcSEcCtD
Nateglinide—Rash—Methotrexate—testicular cancer	0.000167	0.00178	CcSEcCtD
Nateglinide—Dermatitis—Methotrexate—testicular cancer	0.000167	0.00178	CcSEcCtD
Nateglinide—Asthenia—Doxorubicin—testicular cancer	0.000165	0.00176	CcSEcCtD
Nateglinide—Dizziness—Epirubicin—testicular cancer	0.000164	0.00175	CcSEcCtD
Nateglinide—Pruritus—Doxorubicin—testicular cancer	0.000162	0.00173	CcSEcCtD
Nateglinide—SLC16A1—female gonad—testicular cancer	0.00016	0.0459	CbGeAlD
Nateglinide—Vomiting—Epirubicin—testicular cancer	0.000158	0.00168	CcSEcCtD
Nateglinide—Nausea—Methotrexate—testicular cancer	0.000157	0.00168	CcSEcCtD
Nateglinide—Diarrhoea—Doxorubicin—testicular cancer	0.000157	0.00167	CcSEcCtD
Nateglinide—Rash—Epirubicin—testicular cancer	0.000156	0.00167	CcSEcCtD
Nateglinide—Dermatitis—Epirubicin—testicular cancer	0.000156	0.00167	CcSEcCtD
Nateglinide—ABCC8—testis—testicular cancer	0.000156	0.0447	CbGeAlD
Nateglinide—Dizziness—Doxorubicin—testicular cancer	0.000152	0.00162	CcSEcCtD
Nateglinide—Nausea—Epirubicin—testicular cancer	0.000147	0.00157	CcSEcCtD
Nateglinide—Vomiting—Doxorubicin—testicular cancer	0.000146	0.00156	CcSEcCtD
Nateglinide—Rash—Doxorubicin—testicular cancer	0.000145	0.00154	CcSEcCtD
Nateglinide—Dermatitis—Doxorubicin—testicular cancer	0.000144	0.00154	CcSEcCtD
Nateglinide—SLC16A1—testis—testicular cancer	0.000142	0.0407	CbGeAlD
Nateglinide—Nausea—Doxorubicin—testicular cancer	0.000136	0.00145	CcSEcCtD
Nateglinide—PPARG—female gonad—testicular cancer	0.000134	0.0385	CbGeAlD
Nateglinide—KCNJ11—lymph node—testicular cancer	0.000123	0.0352	CbGeAlD
Nateglinide—PTGS1—seminal vesicle—testicular cancer	0.000122	0.035	CbGeAlD
Nateglinide—ABCC4—female gonad—testicular cancer	0.000122	0.0349	CbGeAlD
Nateglinide—PPARG—testis—testicular cancer	0.000119	0.0341	CbGeAlD
Nateglinide—ALB—testis—testicular cancer	0.000112	0.032	CbGeAlD
Nateglinide—ABCC4—testis—testicular cancer	0.000108	0.031	CbGeAlD
Nateglinide—SLC15A2—female gonad—testicular cancer	0.000105	0.0301	CbGeAlD
Nateglinide—SLC16A1—lymph node—testicular cancer	0.000103	0.0295	CbGeAlD
Nateglinide—SLC15A2—testis—testicular cancer	9.32e-05	0.0267	CbGeAlD
Nateglinide—ORM1—lymph node—testicular cancer	9.24e-05	0.0265	CbGeAlD
Nateglinide—PPARG—lymph node—testicular cancer	8.63e-05	0.0247	CbGeAlD
Nateglinide—ALB—lymph node—testicular cancer	8.1e-05	0.0232	CbGeAlD
Nateglinide—CYP3A5—female gonad—testicular cancer	7.99e-05	0.0229	CbGeAlD
Nateglinide—ABCC4—lymph node—testicular cancer	7.84e-05	0.0225	CbGeAlD
Nateglinide—PTGS1—female gonad—testicular cancer	7.18e-05	0.0206	CbGeAlD
Nateglinide—SLC15A2—lymph node—testicular cancer	6.76e-05	0.0194	CbGeAlD
Nateglinide—PTGS1—testis—testicular cancer	6.37e-05	0.0182	CbGeAlD
Nateglinide—CYP2D6—female gonad—testicular cancer	5.9e-05	0.0169	CbGeAlD
Nateglinide—CYP2D6—testis—testicular cancer	5.23e-05	0.015	CbGeAlD
Nateglinide—PTGS1—lymph node—testicular cancer	4.62e-05	0.0132	CbGeAlD
